[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100516474":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":31,"centralContacts":42,"locations":52,"responsibleParty":83,"collaborators":86,"id":91,"slug":46,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":92,"sex":98,"minAge":99,"maxAge":46,"enrollmentInfo":100,"targetDuration":46,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":55,"whyStopped":46,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Dupilumab 300 mg q2w","ACTIVE_COMPARATOR","Dupilumab s.c. 300 mg every 2 weeks for 24 weeks.",[13],"Drug: Dupilumab",{"label":15,"type":16,"description":17,"interventionNames":18},"Dupilumab 300 mg q3w","EXPERIMENTAL","Dupilumab s.c. 300 mg every 3 weeks for 24 weeks.",[13],{"label":20,"type":16,"description":21,"interventionNames":22},"Dupilumab 300 mg q4w","Dupilumab s.c. 300 mg every 4 weeks for 24 weeks.",[13],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Dupilumab","Administering Dupilumab 300 mg at different dosing intervals.",[9,15,20],[30],"Dupixent",[32,36,39],{"name":33,"affiliation":34,"role":35},"Louise AA Gerbens, MD PhD","Amsterdam UMC, location VUmc","STUDY_CHAIR",{"name":37,"affiliation":34,"role":38},"Phyllis I Spuls, MD PhD","PRINCIPAL_INVESTIGATOR",{"name":40,"affiliation":41,"role":38},"DirkJan Hijnen, MD PhD","Erasmus Medical Center",[43,48],{"name":37,"role":44,"phone":45,"phoneExt":46,"email":47},"CONTACT","+3120 566 9111",null,"ph.i.spuls@amsterdamumc.nl",{"name":49,"role":44,"phone":50,"phoneExt":46,"email":51},"Anouk GM Caron, MD","+31653704573","a.caron@amsterdamumc.nl",[53,69],{"facility":54,"status":55,"city":56,"state":57,"zip":58,"country":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Amsterdam University Medical Centers","RECRUITING","Amsterdam","North Holland","1105 AZ","Netherlands",{"type":61,"coordinates":62},"Point",[63,64],4.88969,52.37403,{"lat":64,"lon":63},[67],{"name":68,"role":44,"phone":46,"phoneExt":46,"email":46},"Anouk Caron, MD",{"facility":41,"status":70,"city":71,"state":72,"zip":73,"country":59,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"NOT_YET_RECRUITING","Rotterdam","South Holland","3015 GD",{"type":61,"coordinates":75},[76,77],4.47917,51.9225,{"lat":77,"lon":76},[80],{"name":40,"role":44,"phone":81,"phoneExt":46,"email":82},"+3110 704 0704","d.hijnen@erasmusmc.nl",{"type":38,"investigatorFullName":84,"investigatorTitle":85,"investigatorAffiliation":5,"oldNameTitle":46,"oldOrganization":46},"Prof. Dr. Phyllis I. Spuls","Prof. Dr. P.I. Spuls",[87,88],{"name":41,"class":6},{"name":89,"class":90},"Prothya Biosolutions","INDUSTRY","100516474",false,"NCT06004986","DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema","DUPI REDUCE Trial (DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema): a Multicenter, Low-intervention, Non-inferiority Randomized Controlled Trial, Embedded in the TREAT NL Registry","DUPI REDUCE","Inclusion Criteria:\n\n* The subject is an adult,\n* Has a diagnosis of AE,\n* Receives dupilumab 300 mg q2w for the treatment of AE,\n* Has controlled disease according to the Treat-to-Target criteria,\n* Agrees to the possibility that the dosage of dupilumab will be lowered,\n* Has voluntarily signed and dated an informed consent prior to any study related procedure.\n\nExclusion Criteria:\n\n* The subjects uses or initiates another systemic immunomodulating therapy for AE or another diagnosis.","ALL","18 Years",{"count":101,"type":102},216,"ESTIMATED","INTERVENTIONAL",[105],"PHASE4","The goal of this randomized controlled trial is to study the (cost)effectiveness of extending the intervals between dupilumab doses in patients with well-controlled atopic eczema, while considering physician- and patient-reported disease severity, quality of life, and dupilumab serum trough levels. Patients will be divided randomly into three groups, receiving dupilumab 300 mg every 2 weeks, every 3 weeks, or every 4 weeks. Researchers will then compare the outcomes among these three groups.",[108,109],"Atopic Dermatitis","Atopic Dermatitis Eczema",[26],"2025-10-06",{"date":113,"type":114},"2025-10-08","ACTUAL",{"date":116,"type":114},"2023-08-14",{"date":118,"type":102},"2025-12-31",{"name":5,"class":6},2]